Innovent Biologics, Inc. (IVBXF)
OTCMKTS · Delayed Price · Currency is USD
12.03
-1.62 (-11.87%)
Sep 8, 2025, 2:50 PM EDT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
$257,593
Profits / Employee
$25,535
Market Cap
22.09B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | 3,279 | 1,297 | 65.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| HealthLynked | 20 |
| CytoDyn | 13 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Innovent Biologics News
- 12 days ago - Innovent Biologics estimates ~50% jump in 2025 revenue - Seeking Alpha
- 12 days ago - Innovent Biologics reports interim results - Seeking Alpha
- 12 days ago - Innovent Announces 2025 Interim Results and Business Updates - PRNewsWire
- 15 days ago - Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study ... - GuruFocus
- 15 days ago - Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer - PRNewsWire
- 5 weeks ago - Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 - PRNewsWire
- 7 weeks ago - Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma - PRNewsWire
- 7 weeks ago - ‘China’s Ozempic’ pioneer inks deal with JD Health for online distribution - South China Morning Post